News & Media
Contact

Home
About Us
Our Approach
Pipeline
Clinical Trials
Patients & Caregivers
- Acute Leukemias
- Head & Neck Cancer
Investors
Careers
News & Media
Contact
Menu Menu

Navigating dose optimization requirements as a small biotech

February 1, 2023/in Currents

https://kuraoncology.com/wp-content/uploads/BioCentury_0201_DB_DoseOptim.png 646 1246 Ellie Solorio /wp-content/uploads/kura-logo.svg Ellie Solorio2023-02-01 08:00:002023-02-07 14:03:52Navigating dose optimization requirements as a small biotech

About Us
Our Commitment
The Story Behind Our Name
Leadership
Board of Directors

Our Approach
Precision Medicines
Overcoming Resistance
Novel Biomarkers

Pipeline
Ziftomenib
Tipifarnib
KO-2806
Posters and Presentations
Scientific Manuscripts
Access to Investigational Drugs Outside a Clinical Study

Clinical Trials
Overview of Clinical Trials
Ziftomenib Clinical Trials
KOMET-001 – AML
KOMET-007 – AML
KOMET-008 – AML
Tipifarnib Clinical Trials
KURRENT-HN – HNSCC
KO-2806 Clinical Trials
FIT-001 – Solid Tumors

Patients & Caregivers
Acute Leukemias
Head & Neck Cancer

Investors
Overview
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Analyst Coverage
FAQs
Contact

Careers
Values
Life at Kura
Benefits
Open Positions

News & Media
Press Releases
News & Perspectives
Expert Perspectives
Media Resources

Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2023 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

On the prickly issues facing the Menin inhibitors

The Medicine Maker Power List 2023: Francis Burrows